Pembrolizumab,Gemcitabine,Cisplatin
Merck
['kn966', 'pembro']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty quality of life data from kn966 (gem/cis +/- pembro) pembrolizumab did not improve quality of life - this is important when assessing the clinical value of the combination. best 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨